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Abstract: Molecular profiling of exhaled volatile organic compounds (VOC) by electronic 
nose technology provides  breathprints  that discriminate  between patients with  different 
inflammatory  airway  diseases,  such  as  asthma  and  COPD.  However,  it  is  unknown 
whether  this  is  determined  by  differences  in  airway  caliber.  We  hypothesized  that 
breathprints obtained by electronic nose are independent of acute changes in airway caliber 
in asthma. Ten patients with stable asthma underwent methacholine provocation (Visit 1) 
and sham challenge with isotonic saline (Visit 2). At Visit 1, exhaled air was repetitively 
collected pre-challenge, after reaching the provocative concentration (PC20) causing 20% 
fall  in  forced  expiratory  volume  in  1  second  (FEV1)  and  after  subsequent  salbutamol 
inhalation. At Visit 2, breath was collected pre-challenge, post-saline and post-salbutamol. 
At each occasion, an expiratory vital capacity was collected after 5 min of tidal breathing 
through  an  inspiratory  VOC-filter  in  a  Tedlar  bag  and  sampled  by  electronic  nose 
(Cyranose  320).  Breathprints  were  analyzed  with  principal  component  analysis  and 
individual  factors  were  compared  with  mixed  model  analysis  followed  by  pairwise 
comparisons.  Inhalation  of  methacholine  led  to  a  30.8  ±   3.3%  fall  in  FEV1  and  was 
followed by a significant change in breathprint (p = 0.04). Saline inhalation did not induce 
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a  significant  change  in  FEV1,  but  altered  the  breathprint  (p  =  0.01).  However,  the 
breathprint  obtained  after  the  methacholine  provocation  was  not  significantly  different 
from that after saline challenge (p = 0.27). The molecular profile of exhaled air in patients 
with asthma is altered by nebulized aerosols, but is not affected by acute changes in airway 
caliber. Our data demonstrate that breathprints by electronic nose are not confounded by 
the level of airway obstruction. 
Keywords:  volatile  organic  compounds;  exhaled  breathprint;  electronic  nose;  pattern 
recognition; airway caliber; bronchial asthma; bronchial provocation 
 
1. Introduction 
Asthma is a chronic inflammatory disorder of the airways characterized by recurrent episodes of 
wheezing and chest
 tightness that are associated with variable airway obstruction.
 Asthma diagnosis is 
established  based  on  symptoms,  measurement  of  lung  function  and  assessment  of  airway 
responsiveness [1]. In addition, the associated airway inflammation can be evaluated by validated  
non-invasive techniques such as sputum eosinophil counts [2] and exhaled nitric oxide level (NO) [3], 
which have shown to be useful in monitoring asthma.  
Exhaled  air  is  a  mixture  of  thousands  of  volatile  organic  compounds  (VOCs)  [4],  which  are 
generated  via  metabolic  pathways  that  may  be  altered  by  lung  diseases.  Identification  and 
quantification of individual VOCs require laboratory methodologies employing gas chromatography 
coupled to mass spectrometry (GC-MS). Indeed, panels of VOCs enable the distinction of smoking 
and non-smoking healthy subjects [5], and can identify lung cancer with sufficient sensitivity and 
specificity  [6].  Less  laborious  peak  pattern  analysis  after  spectrometry  without  direct  VOC 
characterization has recently been successful in recognizing lung cancer patients [7]. Nevertheless, the 
procedure  still  requires  skilled  personnel  and  advanced  technical  facilities,  limiting  potential 
widespread medical applicability. 
Electronic nose (eNose) technology provides a cost-effective on-site alternative for breath analysis. 
eNoses exploit arrays of broadly cross-reactive sensors responding to a variety of VOCs in a highly 
sensitive and reversible manner within a short response time [8,9]. eNoses generate a molecular profile 
of  the  VOC  mixture  in  exhaled  breath  also  called  the  breathprint,  and  allow  analysis  by  pattern 
recognition  algorithms  for  discrimination  between  individual  breathprints  without  identifying  the 
individual analytes. An eNose with carbon black polymer was able to predict pneumonia in ventilated 
patients [10], distinguish patients with lung cancer from COPD [11], discriminate asthma patients from 
controls  [12]  and  from  COPD  patients  [13].  In  addition,  an  array  of  sensors  based  on  gold 
nanoparticles was able to distinguish lung cancer patients from controls [14] and an electronic nose 
with  quartz  microbalance  gas  sensors  could  also  discriminate  asthma  patients  from  healthy  
subjects [15]. Due to easy sampling procedures, portability and relatively low cost, eNose technology 
might be useful in medical decision making [16], which requires strict procedures to assess diagnostic 
accuracy (www.stard-statement.org). Sensors 2010, 10                         
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Although the discriminative potential by eNoses is encouraging, patient-related and methodological 
issues have been raised concerning breath collection and analysis [15,17]. Expiratory volume and flow 
need to be standardized [12], but it is unknown whether the breathprints can be modulated by airway 
caliber. For exhaled NO it has been reported that airway narrowing leads to a reduction of exhaled NO 
in asthma [18,19], although this could not be confirmed in another study [20]. A salbutamol-induced 
acute increase in airway caliber may elevate exhaled NO level [21], although this is not a consistent 
finding [19,22]. Thus, it cannot be excluded that other exhaled components, such as VOCs, are also 
affected  by  acute  changes  in  airway  caliber.  If  so,  this  might  complicate  the  interpretation  of 
breathprints in general and particularly in asthma.  
Therefore,  the  null-hypothesis  of  this  study  was  that  breathprints  assessed  by  electronic  nose 
technology are not affected by airway caliber. To investigate this we recorded breathprints before and 
at acute changes in airway caliber during methacholine provocation in asthmatic patients. A control 
challenge with nebulised isotonic saline was performed to examine any confounding effects of the 
challenge procedure on the breathprint. Finally, we assessed the between-day variability in asthmatics 
by comparing pre-challenge baseline breathprints. 
2. Experimental Section 
2.1. Study design 
The  effect  of  bronchoconstriction  on  exhaled  breathprints  was  examined  in  a  cross-over  study 
performed on asthma patients (n = 10) attending two visits with a mean time between visits of 7.5 days 
(range 4–14 days) at a similar time of the day (±  2 h). At Visit 1, methacholine (MCh) provocation and 
at  Visit  2,  a  sham  challenge  with  isotonic  saline  was  performed.  At  Visit  1  exhaled  breath  was 
collected  before  MCh  provocation  (baseline),  when  at  least  a  20%  drop  in  FEV1  was  achieved  
(post-methacholine) and after salbutamol inhalation (post-salbutamol). At Visit  2, exhaled air was 
collected before sham challenge (baseline), after the last inhalation of saline (post-saline) and after 
salbutamol inhalation (post-salbutamol). Subjects were not blinded to the procedures and visits were 
not randomized because of the need to match the number of inhaled doses between the visits. 
The effect of methodological drifts in eNose signals was investigated in a control study performed 
in 10 volunteers (seven healthy, three asthmatics: see below). Breath sampling was performed three 
times following the same course as during the challenge procedures in the main study but without any 
intervention (0 min, 60 min and 90 min). Subjects did not eat and drank only water during and 3 hours 
prior to that period. 
2.2. Subjects 
Ten adult patients with previously diagnosed asthma agreed to participate in the main study. The 
patients were never-smokers and had episodic chest tightness or wheezing with a pre-bronchodilator 
FEV1  >65%  predicted  and  documented  airway  responsiveness  (PC20  methacholine  <8  mg/mL)  or 
reversibility in FEV1 predicted >12% after 400 g inhaled salbutamol as established within 12 months 
prior  to  the  study.  Subjects  with  concurrent  pulmonary  disorders,  diabetes  mellitus,  hypo-  or  
hyper-thyroidism, severe cardiovascular disease, renal insufficiency, present cancer or cancer in the Sensors 2010, 10                         
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past 5 years, oral corticosteroid use, present parodontitis or recent dental treatment were excluded. 
Patients  on  inhaled  medications  other  than  short-acting  or  long-acting  β2-agonists  and/or  inhaled 
steroids or those who had a history of upper or lower respiratory tract infection in the four weeks 
before the measurements were excluded from the study.  
Ten volunteers, including seven healthy non-smoking subjects with no previous history of airway 
diseases or other chronic diseases, and three asthmatics but otherwise healthy patients, without an 
upper or lower respiratory tract infection in the four weeks before the measurements, were recruited to 
participate  in  the  control  study  for  eNose  drift  analysis.  The  protocol  was  approved  by  the  local 
medical ethics committee. Written informed consent was obtained from all subjects. 
2.3. Methacholine and sham challenges 
MCh challenge test was performed according to the 2-min tidal breathing method [23]. The patients 
inhaled methacholine with tidal breathing for 2 min, and FEV1 was recorded 30 s and 90 s after the 
exposure  (MasterscreenPneumo;  Jaeger;  Wü rzburg,  Germany).  Doubling  doses  of  methacholine 
bromide ranging from 0.04 to 19.6 mg/mL were applied in 5-min intervals until PC20 was achieved. 
PC20 was calculated with linear interpolation. Subsequently, the patients inhaled 400 g salbutamol per 
metered dose inhaler with a spacer, and after 10 min FEV1 was measured. FEV1 was considered to be 
restored if higher than 90% of baseline. 
Sham challenge with 0.9% isotonic saline solution (154 mM NaCl) was performed in identical 
fashion with identical numbers of aerosol inhalations and spirometric maneuvers as performed when 
achieving PC20.  
Patients  withheld  long-acting  β2  agonists  and  antihistamines  for  48  hours,  and  short-acting  
β2 agonists and inhaled corticosteroids >8 hours before both challenge tests.  
2.4. Exhaled breath collection and electronic nose sampling 
To reduce possible confounding effects, patients were asked not to eat and drink anything but water 
3 h prior to breath collection and refrain from caffeine-containing beverages and peppermint exposure 
for 6 hours before the visits. Breath collection and sampling were performed using the 5-min tidal 
washin  method  [12].  Briefly,  patients  inhaled  VOC-filtered  air  (A2,  North  Safety,  Middelburg, 
Netherlands) and exhaled via a silica reservoir in a 2-way non-rebreathing valve (Hans Rudolph 2700, 
Hans Rudolph, Kansas City, MI, US). Following 5 min of equilibration with tidal breathing, patients 
performed  a  maximal  inspiratory  capacity  maneuver  and  the  full  expiratory  capacity  volume  was 
collected into a 10-L Tedlar bag. Bags were sampled within ten minutes followed by the parallel 
sampling of another Tedlar bag containing VOC-filtered room air as a reference.  
Exhaled breath samples were analyzed at room temperature by the same handheld electronic nose 
(Cyranose  320;  Smiths  Detection,  Pasadena,  CA,  US)  with  an  array  of  32  carbon  black  polymer 
sensors [8,9]. VOCs binding to a sensor cause a change in the electrical resistance of the sensor. The 
raw data of a breathprint compose of 32 values each corresponding to the relative change in electrical 
resistance  of  a  sensor.  According  to  the  manufacturer’s  instruction,  the  first  measurement  was 
disregarded at each session (first sniff effect). Sensors 2010, 10                         
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2.5. Data analysis 
Sensor data of the eNose were processed through Savitzky-Golay filtering and baseline correction. 
Offline analysis of raw data was performed using SPSS software (version 16.0). Principle component 
analysis was used to redistribute the variance of the original 32 sensors into a set of factors (four 
factors captured 95.6% of the variance within the data set in the main study and 97.3% of the variance 
at the control visit). The two factors (denoted as Factor 2 and Factor 3) which showed a significant 
response to methacholine and/or salbutamol inhalation were selected for further analysis and are being 
referred to as “the breathprint”.  
A mixed model analysis followed by pairwise comparisons on factors was used to evaluate any 
change in breathprints when recorded repetitively during the visits. To compare the changes (deltas) in 
breathprints  caused  by  nebulisation  with  methacholine  and  isotonic  saline,  corresponding  baseline 
factors  were  subtracted  from  post-methacholine  or  post-saline  factors,  and  these  changes  were 
compared  with  paired  t-tests  for  each  factor.  To  assess  between-day  variability  of  a  breathprint, 
baseline factors at visits were compared with paired t-tests.   
There are no previous data for calculation of the statistical power of studies with serial eNose 
measurements.  However, previous parallel  studies  have shown adequate power at  similar samples  
sizes [11,12]. Therefore, the current sample size was considered to be adequate for within-subject 
analysis. 
FEV1 values recorded within a visit were compared with mixed model linear followed by pairwise 
comparison, the percentage change in FEV1 at the visits and baseline FEV1 values between visits were 
analyzed  with  paired  t-tests.  Data  were  normally  distributed  (Kolmogorov-Smirnov  test)  and  are 
expressed as mean ±  SEM in the figures and as mean ±  SD in the table and in the text. The level of 
significance was considered as p < 0.05. 
3. Results and Discussion 
3.1. Study population 
Patient  characteristics  and  baseline  lung  function  parameters  are  presented  in  Table  1.  The 
population was well-characterized, but we acknowledge that the number of subjects in this study was 
limited. Even though data for formal power calculations of serial eNose measurements are lacking, 
similar numbers of patients were successfully used in previous eNose studies [11,12] as well as in 
former  studies  on  the  effects  of  airway  caliber  on  exhaled  NO  [18,20]  based  on  adequate  power 
calculations. Sensors 2010, 10                         
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Table  1.  Patient  characteristics.  Spirometric  data  are  pre-challenge  baseline  values  at  
Visit 2. FVC: forced vital capacity, FEV1: forced expiratory volume in 1 s, ICS: inhaled 
corticosteroids,  Bud  Eq:  budesonide  equivalent,  PC20:  provocative  concentration  of 
methacholine causing 20% fall in FEV1, MCh: methacholine, Post-salb: post-salbutamol 
inhalation.  
Patient 
Number  Sex  Age, 
years 
Daily ICS 
(bud eq, 
µ g) 
Baseline 
FVC, % 
predicted 
Baseline 
FEV1, % 
predicted 
Baseline 
FEV1/FVC 
PC20 MCh, 
mg/mL 
FEV1 change  
at Visit1
& 
FEV1 change 
at Visit2
& 
PC20 
MCh 
Post-
salb 
Post-
saline 
Post-
salb 
1  F  33  400  102  89  0.76  12.93  −26  0  −4  +6 
2  F  27  800  119  104  0.77  5.18  −54  −7  −1  +13 
3  M  29  400  99  82  0.71  0.22  −24  0  −6  0 
4  M  35  200  129  106  0.67  6.93  −24  +7  −11  +2 
5  M  47  200  128  84  0.53  0.76  −28  +7  −8  +11 
6  F  33  0  108  98  0.80  1.33  −39  0  −1  +10 
7  F  23  200  103  101  0.85  3.13  −36  −1  0  −3 
8  F  30  0  106  92  0.85  0.31  −20  +7  −1  +11 
9  M  30  800  88  72  0.67  0.58  −21  −1  −4  +11 
10  F  45  200  87  79  0.78  1.39  −26  −4  −3  +11 
    33 ±  8  400 ±  262
#  107 ±  15  91 ±  12  0.74 ±  0.01  1.55 
(0.59–4.10)  −31 ±  11  1 ±  5  −4 ±  4  7 ±  6 
& Change in percentage compared to corresponding baseline FEV1 values. 
# Only ICS users considered. Data are 
expressed as mean ±  SD or geometric mean (95% confidence interval). 
3.2. Methacholine and sham challenges modify breathprints  
To investigate the effect of airway caliber on exhaled breathprints, we chose a controlled, cross-
over  challenge  model  with  methacholine  as  well  as  sham  (saline)  provocation.  This  allowed  the 
distinction in outcomes as produced by methacholine and inhaled aerosols or the procedure as such. 
As  expected,  methacholine  inhalation  induced  significant  bronchoconstriction  (baseline  FEV1  
3.33 ±  0.63 L vs. 2.30 ±  0.57 L post-methacholine, p < 0.001), and subsequently, airway caliber was 
restored  by  salbutamol  inhalation  [post-salbutamol  FEV1  3.37  ±   0.72  L,  p  <  0.001,  Figure  1(a)]. 
Breathprints, as demonstrated by Factor 2, were significantly changed after methacholine (p = 0.04) 
and also post-salbutamol (p = 0.006) when compared to the breathprints at baseline; however, the 
breathprints  after  salbutamol  were  not  significantly  different  from  the  ones  after  methacholine  
[p = 0.34, Figure 1(b)].  Sensors 2010, 10                         
 
 
9133 
Figure 1. (a) FEV1 measurements at baseline, after methacholine (Post-MCh) inhalation 
and post-salbutamol (Post-salb). (b) Breathprints at baseline, after methacholine inhalation 
and  post-salbutamol  are  presented  by  plotting  Factor  2  (red  line)  and  3  (blue  line).  
*p < 0.05, **p < 0.01, *** p < 0.001 vs. baseline; 
###p < 0.001 vs. post-methacholine. The 
data are shown in the table below the figure. 
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Patient Number 
FEV1, Litre  Factor 2  Factor 3 
Baseline  Post-MCh  Post-Salb  Baseline  Post-MCh  Post-Salb  Baseline  Post-MCh  Post-Salb 
1  2.27  1.68  2.25  0.46  0.11  -1.42  0.61  -0.32  1.32 
2  3.90  1.80  3.64  0.08  -0.24  -0.09  1.03  -0.29  -0.17 
3  3.37  2.56  3.38  1.34  -0.19  0.32  -0.72  0.57  -0.77 
4  4.28  3.24  4.59  2.00  1.52  0.55  1.57  -0.58  0.67 
5  3.52  2.52  3.76  1.89  0.81  0.94  -1.21  -1.38  -1.45 
6  3.17  1.94  3.18  0.62  -0.05  -0.14  0.80  0.96  1.34 
7  3.41  2.20  3.38  -0.58  -1.49  -0.28  -0.72  -0.29  -0.33 
8  3.69  2.96  3.95  -1.20  -0.31  -1.75  -0.33  -2.15  -0.15 
9  3.33  2.63  3.30  -1.25  -1.35  -0.92  -0.12  -0.39  -1.18 
10  2.33  1.50  2.23  0.89  0.26  -0.54  1.52  0.63  1.54 
 
Inhalation of isotonic saline did not change FEV 1 (baseline 3.40 ±  0.72 L vs. post-saline FEV1  
3.27  ±   0.65  L,  p  =  0.13),  but  FEV1  increased  to  3.63  ±   0.73  L  after  salbutamol  inhalation  
[post-salbutamol vs. baseline and post-saline: p = 0.008 and p < 0.001, Figure 2(a)]. Breathprints were 
significantly  changed  post-saline  (Factor  3:  p  =  0.01)  and  post-salbutamol  (Factor  2:  p  =  0.02,  
Factor 3: p = 0.03) when compared to the breathprints at baseline. The post-salbutamol breathprint was 
also altered as compared to post-saline [Factor 2: p = 0.02, Figure 2(b)]. 
Our primary aim was to study the effect of bronchoconstriction on breathprints, but we additionally 
analyzed the effect of acute bronchodilation induced by salbutamol after the provocation test. Our data 
show  that  an  acute  and  marked  increase  in  airway  caliber  after  methacholine  challenge  does  not 
modify  exhaled  breathprints.  Nevertheless,  we  cannot  exclude  any  carry-over  effect  of  inhaled 
methacholine on the post-salbutamol breathprints. Notably, the small but significant increase in airway 
caliber by salbutamol following sham provocation unexpectedly altered the breathprint. We cannot 
explain this observation and its inconsistency with regard to giving salbutamol after methacholine 
challenge. It may suggest that salbutamol inhalation in the absence of methacholine challenge as such 
provided a signal on the breathprint similar to the sham challenge with inhaled saline. Sensors 2010, 10                         
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Figure 2. (a) FEV1 measurements at baseline, after saline inhalation and post-salbutamol 
(post-salb).  (b)  Breathprints  at  baseline,  after  saline  inhalation  and  post-salbutamol  are 
presented by plotting Factor 2 (red line) and 3 (blue line). *p < 0.05, **p < 0.01 vs. baseline; 
#p < 0.05, 
###p < 0.001 vs. post-saline. The data are shown in the table below the figure. 
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Patient Number 
FEV1, Litre  Factor 2  Factor 3 
Baseline  Post-MCh  Post-Salb  Baseline  Post-MCh  Post-Salb  Baseline  Post-MCh  Post-Salb 
1  2.36  2.27  2.48  −0.12  1.44  −0.53  0.25  −1.39  −0.93 
2  3.75  3.79  4.22  0.72  0.26  −0.26  1.78  0.40  0.01 
3  3.82  3.61  3.80  0.56  0.95  1.04  0.47  −0.38  −1.02 
4  4.79  4.29  4.88  0.50  0.40  0.16  2.11  0.72  0.50 
5  3.30  3.04  3.68  −0.65  −1.00  −3.45  0.21  −0.75  0.92 
6  3.31  3.27  3.65  0.11  0.13  0.18  −0.27  0.24  0.12 
7  3.51  3.51  3.40  −0.27  −0.44  −2.50  −0.16  −0.93  −0.07 
8  3.63  3.60  4.03  0.43  0.21  −0.57  −2.28  −1.37  −1.77 
9  3.30  3.14  3.63  0.28  −0.34  0.49  1.09  0.24  0.35 
10  2.27  2.20  2.51  0.88  1.04  0.70  1.40  0.36  0.16 
 
As temporal  drift  in polymer sensors  due to incomplete desorption of molecules from sensor 
surfaces has been reported [24], a control study was done, in which non-smoking volunteers followed 
the same course of three repeated eNose analyse s without any intervention. We found no significant 
temporal change in the four factors analyzed  (0 min vs. 60 min vs. 90 min; Factor 1: 0.12 ±  0.94 vs. 
−0.50 ±  0.97 vs. 0.38 ±  0.97, p = 1.00; Factor 2: 0.61 ±  0.91 vs. −0.07 ±  0.99 vs. −0.54 ±  0.82, p = 
0.66; Factor 3: 0.52 ±  1.22 vs. −0.17 ±  0.84 vs. −0.34 ±  0.75, p = 0.16; Factor 4: −0.23 ±  1.22 vs. 0.01 
±  0.86 vs. 0.23 ±  0.93, p = 1.00). This suggests that the change in breathprints observed during the 
challenge procedures is not the result of sensor drifts in the eNose. 
3.3. Changes in breathprints are not related to bronchoconstriction 
As  expected,  the  decrease  in  FEV1  by  MCh  provocation  was  more  marked  than  after  saline  
[−30.8 ±  10.5% vs. −3.7 ±  3.8%, p < 0.001, Figure 3(a)]. However, there was no significant difference 
between the changes (deltas) in breathprints as induced by MCh provocation and sham challenge [delta 
Factor 2: p = 0.27, delta Factor 3: p = 0.66, Figure 3(b)]. Sensors 2010, 10                         
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Figure 3. (a) Changes in FEV1 after the inhalation of methacholine (MCh; orange line) or 
isotonic saline (black line). (b) Changes in breathprints induced by methacholine or saline 
inhalation as the change (delta) in Factor 2  (red line) and 3 (blue line); for all deltas:  
p > 0.05. 
§ § §p < 0.001 post-methacholine vs. post-saline. 
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        Patient 
number 
Δ Factor 2 
 
Δ Factor 3 
        MCh provocation  Saline inhalation  MCh provocation  Saline inhalation 
          1  −0.39  −1.49  −0.78  −0.04 
          2  0.15  −0.41  −1.28  −1.25 
          3  −1.64  −0.66  0.78  −0.29 
          4  −0.30  −1.49  −1.86  −1.28 
          5  −1.60  −0.73  −0.23  −0.91 
          6  −0.40  −0.69  −0.36  0.59 
          7  −1.50  −0.52  0.26  −0.18 
          8  1.36  −0.63  −1.39  0.32 
          9  0.38  −0.71  −0.51  −1.30 
          10  −0.27  −0.72  −0.76  0.52 
 
How can these results be explained? The similar changes in breathprint after challenges with 
methacholine and isotonic saline indicate that alterations in breathprint might be due to the 
nebulisation procedure itself rather than to the change in airway  caliber. We used a previously 
validated sampling technique with filtering of VOCs in inspired air and  drying of exhaled air [12] in 
order to minimize the influence of humidity, expiratory flow rate and environmental VOCs on the 
exhaled VOC mixture. Although exhaled air is fully saturated, even under physiological conditions, we 
cannot exclude an effect of humidity on the breathprints after inhaling nebulized solutions. The current 
findings suggest that the drying step in the breath collection procedure may need to be optimized when 
used after aqueous nebulization. This issue might be particularly relevant i n future studies where 
patients are subjected to nebulized therapies. An alternative explanation is that isotonic saline (alone or 
as a diluent for MCh), having a chloride concentration of 154 mM that is higher than that of the 
epithelial lining fluid (115 mM), induces metabolic changes in the bronchial epithelium [25]. If so, this 
could affect exhaled VOC profile thereby modifying exhaled breathprints. This possibility might be 
examined by local bronchoscopic fluid installation and air sampling. 
3.4. Breathprints do not show between-day variability in asthma patients 
Baseline FEV1 values were similar between the two visits (Visit 1: 3.33 ±  0.63 L  vs. Visit 2:  
3.40  ±   0.72  L,  p  =  0.34),  and  neither  was  there  a  significant  difference  in  baseline  breathprints  
(Factor 2: p = 0.92, Factor 3: p = 0.18, Figure 4). These findings demonstrate that breathprints do not 
show between-day variability in non-smoking asthma patients. This extends a previous study reporting Sensors 2010, 10                         
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no differences in breathprints in healthy smoking and non-smoking control subjects when recorded at 
two separate days [13]. As variability of breathprints is an important issue in the standardization of 
breath analysis, further large-scale studies should confirm these findings. 
Figure 4. Baseline breathprints are unchanged in asthmatic patients. Pre-challenge baseline 
breathprints at the two visits are shown by plotting Factor 2 (red line) and Factor 3 (blue 
line); for all factors: p > 0.05. The attached table shows the data. 
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Patient number 
Factor 2  Factor 3 
Visit 1  Visit 2  Visit 1  Visit 2 
1  0.78  -0.24  0.59  0.38 
2  −0.28  0.32  0.95  1.79 
3  1.52  0.28  −0.42  0.89 
4  1.86  1.89  1.33  2.01 
5  2.35  0.71  −0.87  −0.45 
6  0.44  0.20  0.98  0.05 
7  −0.30  −0.24  −0.72  −0.60 
8  −1.71  −0.62  −0.53  −1.06 
9  −1.69  0.97  −0.21  1.21 
10  0.92  0.24  1.31  1.67 
         
4. Conclusions 
This study shows that an acute decrease in airway caliber per se is not associated with an altered 
breath  molecular  profile  in  asthma  as  measured  by  an  electronic  nose.  This  suggests  that  eNose 
assessment  in  asthma  does  not  require  correction  for  the  degree  of  airway  obstruction.  We  also 
demonstrate  that  inhaled  nebulized  aerosols  can  change  breathprints  irrespective  of  the  change  in 
airway caliber. Finally, breathprints by an eNose do not show significant between-day changes in 
stable asthma.  
These findings imply that the previously observed discrimination of patients with asthma, COPD 
and controls by breathprint analysis [12,13,15] is due to the differences in underlying inflammation or 
disease activity rather than the level of airway obstruction. The clinical implication of this study is that 
monitoring of patients with asthma with repeated eNose assessments can be performed, regardless of 
acute changes in airway caliber. Exhaled molecular profiles may still vary with the degree of airway 
obstruction  if  the  latter  goes  along  with  changes  in  airway  inflammation.  This  strengthens  the 
applicability of eNose technology in the future monitoring of diseases with variable airway obstruction 
and  facilitates  further  studies  on  the  validation  of  eNose  monitoring  in  patients  with  asthma  and 
COPD.  
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